FTC Compliance for Women's Health Brands: From PMS to Menopause Claims

Women's health is one of the most actively litigated and FTC-watched categories in consumer wellness. The FTC's 2022 Health Products Compliance Guidance reset expectations for what qualifies as adequate substantiation, and the women's wellness boom — especially in fertility, perimenopause, menopause, hormonal balance, and PMS — has put the category squarely in the enforcement spotlight. This guide is what every women's health brand should understand before publishing a claim, sending an influencer brief, or designing a label. The substantiation standard For women's health products, the FTC requires "competent and reliable scientific evidence" — typically defined as well-designed human studies. Mechanism-of-action papers, ingredient studies on majority-male cohorts, or animal studies are not enough on their own. The agency expects evidence on the actual finished product, in the actual target population (women, often life-stage specific), measured with validated instruments. Structure-function vs. disease claims For supplements, the dietary supplement framework permits structure-function claims but prohibits disease claims. The line matters more in women's health than almost anywhere else because so many women's products sit adjacent to diagnosable conditions — endometriosis, PCOS, infertility, depression, osteoporosis. Structure-function (allowed): "Supports healthy menstrual cycles," "helps maintain hormonal balance," "promotes normal bone health." Disease (not allowed without drug approval): "Treats endometriosis," "prevents osteoporosis," "cures infertility," "reduces hot flashes" (this last one is widely litigated — the safer phrasing is "helps maintain comfort during the menopausal transition"). Common pitfalls in women's health claims Borrowing ingredient studies. A study on diindolylmethane in women aged 45+ does not substantiate a claim for a finished multivitamin marketed to 25-year-olds. Influencer-amplified disease claims. A creator saying "this fixed my PCOS" can be attributed to the brand under the FTC Endorsement Guides, even if the brand never made that claim itself. Pregnancy and breastfeeding silence. If a product is contraindicated in pregnancy, the label and PDP need to say so. Plaintiffs' firms look for omissions. "Doctor-formulated" without substantiation. Acceptable as a description of how the product was developed; not acceptable as a stand-in for clinical evidence. Comparative claims. "More effective than [competitor]" requires head-to-head data — which almost no brand actually has. Building a defensible evidence file For each marketed claim, you should be able to produce: (a) the protocol and IRB approval, (b) the final study report with primary and secondary endpoint analysis, (c) a claim mapping document showing how each marketing line traces back to an endpoint, and (d) the regulatory review of the claim language. Citruslabs builds this evidence file as part of every women's health study so brands can respond to FTC inquiries, retailer review boards, and Amazon listing audits without scrambling.